Korean J Bone Metab > Volume 10(2); 2003 > Article
Korean Journal of Bone Metabolism 2003;10(2):175-183.
Preference Study of Oral Alendronate 10 mg Once Daily and Alendronate 70 mg Once Weekly in Korean Postmenopausal Women with Low Bone Mass
낮은 골밀도를 가진 한국인 폐경후 여성에서 1일 1회 알렌드로네이트 10 mg과 1주 1회 알렌드로네이트 70 mg 경구 투여의 선호도 조사
김현진,지재환,정윤재,이병완,강한욱,김지연,정재훈,이명식,이문규,김광원,민용기
성균관대학교 의과대학 삼성서울병원 내분비-대사 내과
Abstract
Background
Osteoporosis is a major public threat for postmenopausal women. The recent availability of once weekly alendronate 70 mg provides an additional treatment option to once daily alendronate 10 mg. In earlier study, both alendronate 70 mg once weekly and alendronate 10 mg once daily were well tolerated with similar incidence of upper gastrointestinal adverse events. Preference, convenience, and overall compliance are key factors in the successful treatment of osteoporosis. The aim of this study was to determine preference for once weekly versus once daily dosing with alendronate, and to determine which treatment regimen the patient considered more convenient and would choose as a long-term treatment method in Korean postmenopausal women with low bone mass.
Methods
Postmenopausal women with low bone mineral density at lumbar or hip (T score of less than -2.0) were randomly assigned to two groups. They received 8 weeks of treatment in crossover fashion (4 weeks with each study regimen: once weekly alendronate 70 mg and once daily alendronate 10 mg). At end of the study, patients completed the questionnaire for the preference, the convenience and the compliance for a long period. Adverse events were recorded to assess patient tolerability and safety.
Results
120 patients received the treatment and 106 completed the study. Of the patients who completed the questionnaire, 78 patients preferred the 70 mg once weekly dosing regimen compared with the 10 mg once daily regimen (73.6% vs 20.8%) Many patients considered the once weekly dosing more convenient than once daily dosing (80.2% vs 16.0%) and would be easier to comply with for a long-period.
Conclusion
When alendronate 70 mg administered once weekly was compared with alendronate 10 mg administered once daily, alendronate 70 mg once weekly was the preferred dosing regimen.
Key Words: Postmenopausal women, Once weekly alendronate, Once daily alendronate, Preference
TOOLS
METRICS Graph View
  • 1,001 View
  • 1 Download
Related articles

The Effects of Alendronate on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Osteoporosis Women 2001 May;8(1)



ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1001, Hyundai Kirim Officetel, 42 Seocho-daero 78-gil, Seocho-gu, Seoul 06626, Korea
Tel: +82-2-3473-2231    Fax: +82-70-4156-2230    E-mail: editors.jbm@gmail.com                

Copyright © 2024 by The Korean Society for Bone and Mineral Research.

Developed in M2PI

Close layer
prev next